Literature DB >> 31973684

Psychedelic Microdosing: Prevalence and Subjective Effects.

Lindsay P Cameron1, Angela Nazarian2, David E Olson3,4,5.   

Abstract

Anecdotal reports suggest that the administration of sub-hallucinogenic doses of psychedelic compounds on a chronic, intermittent schedule - a practice known as psychedelic microdosing - is becoming increasingly popular among young adults due to its purported ability to reduce symptoms of depression and anxiety while improving cognitive function and promoting social interaction. Using an anonymous online survey, we collected data from 2347 people to 1) assess the prevalence of psychedelic microdosing and characterize the demographics of microdosers, 2) determine whether microdosers associate the practice with changes in mood, cognitive function, social interaction, or physiology, and 3) investigate frequent motives for discontinuing the practice. Fifty-nine percent of respondents (NT = 2183) reported familiarity with the concept of psychedelic microdosing, with 17% (383 respondents, NT = 2200) having engaged in this practice. Microdosers attributed psychedelic microdosing with improving their mood, decreasing their anxiety, and enhancing their memory, attention, and sociability. The most frequently cited reasons for quitting microdosing (NT = 243) were the risks associated with taking an illegal substance (24.28%) and the difficulty of obtaining psychedelic compounds (22.63%). Overall, our findings suggest that psychedelic microdosing is relatively common and is subjectively associated with a broad spectrum of socio-affective, cognitive, and physical outcomes.

Entities:  

Keywords:  LSD; PTSD; Psychedelic; anxiety; depression; microdosing

Mesh:

Substances:

Year:  2020        PMID: 31973684      PMCID: PMC7282936          DOI: 10.1080/02791072.2020.1718250

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  46 in total

Review 1.  Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.

Authors:  Harvey A Whiteford; Louisa Degenhardt; Jürgen Rehm; Amanda J Baxter; Alize J Ferrari; Holly E Erskine; Fiona J Charlson; Rosana E Norman; Abraham D Flaxman; Nicole Johns; Roy Burstein; Christopher J L Murray; Theo Vos
Journal:  Lancet       Date:  2013-08-29       Impact factor: 79.321

2.  Cost of disorders of the brain in Europe 2010.

Authors:  Anders Gustavsson; Mikael Svensson; Frank Jacobi; Christer Allgulander; Jordi Alonso; Ettore Beghi; Richard Dodel; Mattias Ekman; Carlo Faravelli; Laura Fratiglioni; Brenda Gannon; David Hilton Jones; Poul Jennum; Albena Jordanova; Linus Jönsson; Korinna Karampampa; Martin Knapp; Gisela Kobelt; Tobias Kurth; Roselind Lieb; Mattias Linde; Christina Ljungcrantz; Andreas Maercker; Beatrice Melin; Massimo Moscarelli; Amir Musayev; Fiona Norwood; Martin Preisig; Maura Pugliatti; Juergen Rehm; Luis Salvador-Carulla; Brigitte Schlehofer; Roland Simon; Hans-Christoph Steinhausen; Lars Jacob Stovner; Jean-Michel Vallat; Peter Van den Bergh; Peter Van den Bergh; Jim van Os; Pieter Vos; Weili Xu; Hans-Ulrich Wittchen; Bengt Jönsson; Jes Olesen
Journal:  Eur Neuropsychopharmacol       Date:  2011-09-15       Impact factor: 4.600

Review 3.  Abnormal mTOR Activation in Autism.

Authors:  Kellen D Winden; Darius Ebrahimi-Fakhari; Mustafa Sahin
Journal:  Annu Rev Neurosci       Date:  2018-01-25       Impact factor: 12.449

4.  Effects of N, N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression.

Authors:  Lindsay P Cameron; Charlie J Benson; Lee E Dunlap; David E Olson
Journal:  ACS Chem Neurosci       Date:  2018-04-24       Impact factor: 4.418

5.  Prophylactic Ketamine Attenuates Learned Fear.

Authors:  Josephine C McGowan; Christina T LaGamma; Sean C Lim; Melina Tsitsiklis; Yuval Neria; Rebecca A Brachman; Christine A Denny
Journal:  Neuropsychopharmacology       Date:  2017-01-27       Impact factor: 7.853

Review 6.  Is it time to revisit the role of psychedelic drugs in enhancing human creativity?

Authors:  B Sessa
Journal:  J Psychopharmacol       Date:  2008-06-18       Impact factor: 4.153

7.  Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning.

Authors:  Briony J Catlow; Shijie Song; Daniel A Paredes; Cheryl L Kirstein; Juan Sanchez-Ramos
Journal:  Exp Brain Res       Date:  2013-06-02       Impact factor: 1.972

8.  3,4-Methylenedioxymethamphetamine facilitates fear extinction learning.

Authors:  M B Young; R Andero; K J Ressler; L L Howell
Journal:  Transl Psychiatry       Date:  2015-09-15       Impact factor: 6.222

9.  The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial.

Authors:  Steliana Yanakieva; Naya Polychroni; Neiloufar Family; Luke T J Williams; David P Luke; Devin B Terhune
Journal:  Psychopharmacology (Berl)       Date:  2018-11-26       Impact factor: 4.530

10.  Psychedelic microdosing benefits and challenges: an empirical codebook.

Authors:  Thomas Anderson; Rotem Petranker; Adam Christopher; Daniel Rosenbaum; Cory Weissman; Le-Anh Dinh-Williams; Katrina Hui; Emma Hapke
Journal:  Harm Reduct J       Date:  2019-07-10
View more
  16 in total

1.  Natural language signatures of psilocybin microdosing.

Authors:  Camila Sanz; Federico Cavanna; Stephanie Muller; Laura de la Fuente; Federico Zamberlan; Matías Palmucci; Lucie Janeckova; Martin Kuchar; Facundo Carrillo; Adolfo M García; Carla Pallavicini; Enzo Tagliazucchi
Journal:  Psychopharmacology (Berl)       Date:  2022-06-09       Impact factor: 4.415

Review 2.  New Paradigms of Old Psychedelics in Schizophrenia.

Authors:  Danish Mahmood; Sattam K Alenezi; Md Jamir Anwar; Faizul Azam; Kamal A Qureshi; Mariusz Jaremko
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-23

3.  Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls.

Authors:  Joseph M Rootman; Maggie Kiraga; Pamela Kryskow; Kalin Harvey; Paul Stamets; Eesmyal Santos-Brault; Kim P C Kuypers; Zach Walsh
Journal:  Sci Rep       Date:  2022-06-30       Impact factor: 4.996

Review 4.  Molecular targets of psychedelic-induced plasticity.

Authors:  Alaina M Jaster; Mario de la Fuente Revenga; Javier González-Maeso
Journal:  J Neurochem       Date:  2021-11-15       Impact factor: 5.546

5.  Dosing Psychedelics and MDMA.

Authors:  Matthias E Liechti; Friederike Holze
Journal:  Curr Top Behav Neurosci       Date:  2022

6.  Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing.

Authors:  L S Kaertner; M B Steinborn; H Kettner; M J Spriggs; L Roseman; T Buchborn; M Balaet; C Timmermann; D Erritzoe; R L Carhart-Harris
Journal:  Sci Rep       Date:  2021-01-21       Impact factor: 4.379

7.  Asking questions of psychedelic microdosing.

Authors:  Lindsay P Cameron
Journal:  Elife       Date:  2021-03-02       Impact factor: 8.140

Review 8.  Toxicology and Analysis of Psychoactive Tryptamines.

Authors:  Sara Malaca; Alfredo Fabrizio Lo Faro; Alice Tamborra; Simona Pichini; Francesco Paolo Busardò; Marilyn A Huestis
Journal:  Int J Mol Sci       Date:  2020-12-04       Impact factor: 5.923

9.  MDLSD: study protocol for a randomised, double-masked, placebo-controlled trial of repeated microdoses of LSD in healthy volunteers.

Authors:  Robin J Murphy; Rachael L Sumner; William Evans; David Menkes; Ingo Lambrecht; Rhys Ponton; Frederick Sundram; Nicholas Hoeh; Sanya Ram; Lisa Reynolds; Suresh Muthukumaraswamy
Journal:  Trials       Date:  2021-04-23       Impact factor: 2.279

Review 10.  Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT.

Authors:  Steven A Barker
Journal:  Psychopharmacology (Berl)       Date:  2022-01-22       Impact factor: 4.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.